New Drugs and Nutraceuticals in the Treatment of Osteoarthritis
Development of Therapeutic Agents Handbook
Published Online: 16 DEC 2011
Copyright © 2010 John Wiley & Sons, Inc. All rights reserved.
Pharmaceutical Sciences Encyclopedia
How to Cite
Henrotin, Y. and Reginster, J.-Y. 2011. New Drugs and Nutraceuticals in the Treatment of Osteoarthritis. Pharmaceutical Sciences Encyclopedia. 454.
- Published Online: 16 DEC 2011
Osteoarthritis is a disease with a multifactorial etiology affecting all joint tissues and involving both biochemical and mechanical factors that act in synergy to degrade cartilage. Until now, OA treatments are limited to pain relief, even if some new drugs of the SYSADOA class have shown potential structure-modifying effects. These drugs target cartilage as the endpoint of joint failure, underestimating the role played by subchondral bone and synovium in this process. However, recent studies emphasized the key role played by subchondral bone sclerosis and synovium inflammation in OA pathophysiology. Unfortunately, until now, there is no validated method for a reliable assessment of structural changes in these tissues, explaining that guidance documents edited by the official agencies and scientific societies are strictly focused on the assessment of cartilage changes.
- subchondral bone sclerosis;
- synovium inflammation;
- methylsulfonylmethane (MSM);